Qingchun Diao
Chongqing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.
Journal: The Journal of dermatological treatment
Published: July 15, 2026
Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.
Journal: The Journal of dermatological treatment
Published: July 06, 2026
Efficacy and Safety of the First Adalimumab Biosimilar in Chinese Children with Severe Plaque Psoriasis: The PISCES Study, a Multicenter Prospective Study.
Journal: Dermatology and therapy
Published: June 02, 2026
Efficacy and Tolerability of a Triple Acid-Containing Serum Combined With 0.1% Adapalene in Mild-to-Moderate Acne Vulgaris: A Randomized, Open-Label Controlled Trial.
Journal: Journal of cosmetic dermatology
Published: January 21, 2026
Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial.
Journal: The Journal of dermatological treatment
Published: November 25, 2025
Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic Dermatitis.
Journal: International journal of dermatology
Published: September 24, 2025
Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II/III clinical trial.
Journal: The British journal of dermatology
Published: August 25, 2025
Anti-IL-4Rα antibody SHR-1819 for moderate-to-severe atopic dermatitis: a randomized phase 2 study.
Journal: BMC medicine
Published: August 13, 2025
Efficacy and Safety of Stapokibart in Adults With Moderate-to-Severe Atopic Dermatitis With and Without Type 2 Comorbidities: A Post Hoc Analysis of a Phase 3 Trial.
Journal: Clinical and translational allergy
Published: July 24, 2025
Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 Trial.
Journal: Advances in therapy
Published: April 08, 2025
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: March 28, 2025
Superior efficacy and comparable safety of calcipotriol plus betamethasone dipropionate foam vs. ointment in Chinese patients with plaque psoriasis: A randomized phase 3 trial.
Journal: Chinese medical journal
Published: March 21, 2025
Last Updated: 09/26/2026